Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?

scientific article published on 3 April 2018

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes? is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1103148499
P356DOI10.1186/S13098-018-0327-4
P932PMC publication ID5883417
P698PubMed publication ID29636825

P2093author name stringRodrigo Oliveira Moreira
Roberta Cobas
Raquel C Lopes Assis Coelho
P2860cites workSafety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trialQ50233425
Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin; DUAL VII Randomized Clinical Trial.Q51246488
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.Q51278923
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.Q51280414
Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).Q51317501
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with typQ53261592
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetesQ26784381
A systematic review of the associations between dose regimens and medication complianceQ30719289
Interventions for helping patients to follow prescriptions for medicationsQ30868125
Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial.Q33834266
Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesQ36050559
IDegLira Versus Alternative Intensification Strategies in Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin TherapyQ36360100
One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trialQ36554610
IDegLira Improves Both Fasting and Postprandial Glucose Control as Demonstrated Using Continuous Glucose Monitoring and a Standardized Meal TestQ36638917
Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 peopleQ37278100
Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetesQ37337304
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical TrialQ37639300
Real-world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic reviewQ38074481
Long-term effectiveness and safety of liraglutide in clinical practice.Q38084102
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical TrialQ38395267
Efficacy and Safety of Degludec versus Glargine in Type 2 DiabetesQ38400563
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balanceQ38542098
Impact of postprandial glucose control on diabetes-related complications: How is the evidence evolving?Q38626133
The Clinical Use of a Fixed-Dose Combination of Insulin Degludec and Liraglutide (Xultophy 100/3.6) for the Treatment of Type 2 DiabetesQ38629197
An Evaluation of the Clinical Therapeutic Effect of Lixisenatide in Type 2 Diabetes Patients: A Systematic Literature ReviewQ38664374
Type 2 Diabetes, Hypoglycemia, and Basal Insulins: Ongoing ChallengesQ39015857
Insulin Glargine/Lixisenatide: A Review in Type 2 DiabetesQ39408293
Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetesQ40105411
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary SyndromeQ41078909
Basal insulin and cardiovascular and other outcomes in dysglycemiaQ42507791
Psychological insulin resistance in patients with type 2 diabetes: the scope of the problemQ46611567
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.Q47556600
8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018.Q49988613
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P921main subjecttype 2 diabetesQ3025883
P304page(s)26
P577publication date2018-04-03
P1433published inDiabetology and Metabolic SyndromeQ15816649
P1476titleCombination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
P478volume10

Reverse relations

cites work (P2860)
Q92128367BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy): Expert Opinion
Q92135193Clinical and psychological characteristics of liraglutide treatment among patients with type 2 diabetes
Q92270000Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
Q92262738Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial
Q92442104IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy
Q89949315Impact of Simultaneous Versus Sequential Initiation of Basal Insulin and Glucagon-like Peptide-1 Receptor Agonists on HbA1c in Type 2 Diabetes: A Retrospective Observational Study
Q90409273The Evolving Treatment of Diabetic Retinopathy

Search more.